| 1 |
Chánez-Paredes S, Montoya-García A, Schnoor M. Cellular and pathophysiological consequences of Arp2/3 complex inhibition: role of inhibitory proteins and pharmacological compounds[J]. Cell Mol Life Sci, 2019, 76(17): 3349-3361.
|
| 2 |
Molinie N, Gautreau A. The Arp2/3 regulatory system and its deregulation in cancer[J]. Physiol Rev, 2018, 98(1): 215-238.
|
| 3 |
Sokolova OS, Chemeris A, Guo S, et al. Structural basis of Arp2/3 complex inhibition by GMF, coronin, and arpin[J]. J Mol Biol, 2017, 429(2): 237-248.
|
| 4 |
Zhang J, Liu Y, Yu CJ, et al. Role of ARPC2 in human gastric cancer[J]. Mediators Inflamm, 2017, 2017: 5432818.
|
| 5 |
侯思南，陈妍珂，顾建美，等. LncSox4在非小细胞肺癌中的表达及生物学作用[J]. 临床检验杂志，2019, 37(10): 731-736.
|
| 6 |
Wang F, Liu Y, Chen Y. Pituitary tumor transforming gene-1 in non-small cell lung cancer: Clinicopathological and immunohistochemical analysis[J]. Biomed Pharmacother, 2016, 84: 1595-1600.
|
| 7 |
Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions[J]. Respirology, 2020, 25(2): 61-71.
|
| 8 |
王洪武，金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
|
| 9 |
Chen P, Liu Y, Wen Y, et al. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10): 937-970.
|
| 10 |
Guo H, Zhao L, Zhu J, et al. Microbes in lung cancer initiation, treatment, and outcome: Boon or bane？[J]. Semin Cancer Biol, 2022, 86(Pt 2): 1190-1206.
|
| 11 |
Muthusamy B, Patil PD, Pennell NA. Perioperative systemic therapy for resectable non-small cell lung cancer[J]. J Natl Compr Canc Netw, 2022, 20(8): 953-961.
|
| 12 |
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nat Med, 2021, 27(8): 1345-1356.
|
| 13 |
Sun Y, Shen W, Hu S, et al. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy[J]. J Exp Clin Cancer Res, 2023, 42(1): 65.
|
| 14 |
Zhang C, Wang H. Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5): 188798.
|
| 15 |
Wu F, Fan J, He Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer[J]. Nat Commun, 2021, 12(1): 2540.
|
| 16 |
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
|
| 17 |
Haarer EL, Theodore CJ, Guo S, et al. Genomic instability caused by Arp2/3 complex inactivation results in micronucleus biogenesis and cellular senescence[J]. PLoS Genet, 2023, 19(1): e1010045.
|
| 18 |
Mergault C, Lisée F, Tiroille V, et al. Inhibition of the Arp2/3 complex represses human lung myofibroblast differentiation and attenuates bleomycin-induced pulmonary fibrosis[J]. Br J Pharmacol, 2022, 179(1): 125-140.
|
| 19 |
Huang S, Li D, Zhuang L, et al. Identification of Arp2/3 complex subunits as prognostic biomarkers for hepatocellular carcinoma[J]. Front Mol Biosci, 2021, 8: 690151.
|
| 20 |
Liu Z, Yang X, Chen C, et al. Expression of the Arp2/3 complex in human gliomas and its role in the migration and invasion of glioma cells[J]. Oncol Rep, 2013, 30(5): 2127-2136.
|
| 21 |
Otsubo T, Iwaya K, Mukai Y, et al. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis[J]. Mod Pathol, 2014, 17(4): 461-467.
|
| 22 |
Choi J, Lee YJ, Yoon YJ, et al. Pimozide suppresses cancer cell migration and tumor metastasis through binding to ARPC2, a subunit of the Arp2/3 complex[J]. Cancer Sci, 2019, 110(12): 3788-3801.
|
| 23 |
Cheng Z, Wei W, Wu Z, et al. ARPC2 promotes breast cancer proliferation and metastasis[J]. Oncol Rep, 2019, 41(6): 3189-3200.
|
| 24 |
Chen P, Yue X, Xiong H, et al. RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression[J]. Int J Oncol, 2019, 54(4): 1387-1397.
|
| 25 |
王亚萍，余军辉，王 凯. 下调ARPC2通过抑制Wnt/β-catenin通路激活水平降低卵巢癌OVCA429细胞恶性转移潜能[J]. 中国现代医生，2021, 59(19): 38-43.
|
| 26 |
Yoon YJ, Han YM, Choi J, et al. Benproperine, an ARPC2 inhibitor，suppresses cancer cell migration and tumor metastasis[J]. Biochem Pharmacol, 2019, 163: 46-59.
|
| 27 |
Şahin S, Batur Ş, Aydın Ö，et al. Programmed death-ligand-1 expression in non-small cell lung cancer and prognosis[J]. Balkan Med J, 2019, 36(3): 184-189.
|
| 28 |
Sun L, Yuan H, Burnett J, et al. MEOX1 promotes tumor progression and predicts poor prognosis in human non-small-cell lung cancer[J]. Int J Med Sci, 2019, 16(1): 68-74.
|
| 29 |
石亚飞，陈 伟，曹 宇，等. 非小细胞肺癌患者预后影响因素分析及预测列线图构建[J]. 中国医院药学杂志，2018, 38(20): 2137-2140，2173.
|
| 30 |
白熠洲，刘安阳，季午阳，等. 肌动蛋白相关蛋白2/3复合体亚基2基因沉默对甲状腺乳头状癌TPC-1细胞增殖和凋亡的影响[J]. 肿瘤研究与临床，2020, 32(2): 73-78.
|
| 31 |
郭 晗. 胆管癌术后复发预测模型的构建及ARPC2调控肝内胆管癌的侵袭及作用机制[D]. 上海交通大学，2020.
|